<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M. Arbyn</style></author><author><style face="normal" font="default" size="100%">L Xu</style></author><author><style face="normal" font="default" size="100%">Cindy Simoens</style></author><author><style face="normal" font="default" size="100%">Martin-Hirsch, Pierre Pl</style></author><author><style face="normal" font="default" size="100%">Bryant, Andrew</style></author><author><style face="normal" font="default" size="100%">Beutels, Philippe</style></author><author><style face="normal" font="default" size="100%">Paraskevaidis, Evangelos</style></author><author><style face="normal" font="default" size="100%">van Hoof, Elke</style></author><author><style face="normal" font="default" size="100%">Steben, Marc</style></author><author><style face="normal" font="default" size="100%">Qiao, Youlin</style></author><author><style face="normal" font="default" size="100%">Zhao, Fang-Hui</style></author><author><style face="normal" font="default" size="100%">Schneider, Achim</style></author><author><style face="normal" font="default" size="100%">Kaufmann, Andreas</style></author><author><style face="normal" font="default" size="100%">Dillner, Joakim</style></author><author><style face="normal" font="default" size="100%">Markowitz, Lauri</style></author><author><style face="normal" font="default" size="100%">Hildesheim, Allan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database Syst Rev</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cochrane Database Syst Rev</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">clinical efficacy</style></keyword><keyword><style  face="normal" font="default" size="100%">immunogenicity</style></keyword><keyword><style  face="normal" font="default" size="100%">prophylactic HPV vaccines</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">2011</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types). We will assess clinical effectiveness by evaluating outcomes in all women, irrespective of the HPV DNA or serology status at enrolment. Evaluation by fine age and time since sexual debut categories is also planned.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/25267916?dopt=Abstract</style></custom1></record></records></xml>